DR. RAVINDRA MAJETI, M.D.
Osteopathic Medicine in Palo Alto, CA
License number
California A86286
Category
Osteopathic Medicine
Type
Hematology
Address
Address
875 Blake Wilbur Dr Stanford Cancer Ctr, Palo Alto, CA 94304
Phone
(650) 723-5007
Organization information
See more information about RAVINDRA MAJETI at bizstanding.comRavindra Majeti MD
875 Blake Wilbur Dr, Palo Alto, CA 94304
Industry:
Internist
Phone:
(650) 723-5007 (Phone)
Ravindra Majeti
Professional information
Ravindra Majeti, Palo Alto CA
Specialties:
Hematologist
Address:
875 Blake Wilbur Dr, Palo Alto, CA 94304
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine)
Ravindra Majeti, Palo Alto CA
Specialties:
Internal Medicine, Hematology, Hematology & Oncology
Work:
Hematology Div
875 Blake Wilbur Dr, Palo Alto, CA 94304 Stanford University
875 Blake Wilbur Dr, Stanford, CA 94305
875 Blake Wilbur Dr, Palo Alto, CA 94304 Stanford University
875 Blake Wilbur Dr, Stanford, CA 94305
Education:
University of California at San Francisco (2002)
Dr. Ravindra Majeti, Palo Alto CA - MD (Doctor of Medicine)
Address:
875 Blake Wilbur Dr STE 2324, Palo Alto 94304
(650) 498-6000 (Phone), (650) 724-5203 (Fax)
STANFORD CANCER CENTER
875 Blake Wilbur Dr STE 2327B, Palo Alto 94304
(650) 736-1253 (Phone), (650) 724-5203 (Fax)
875 Blake Wilbur Dr STE 2324, Palo Alto 94304
(650) 498-6000 (Phone), (650) 724-5203 (Fax)
STANFORD CANCER CENTER
875 Blake Wilbur Dr STE 2327B, Palo Alto 94304
(650) 736-1253 (Phone), (650) 724-5203 (Fax)
(650) 498-6000 (Phone), (650) 724-5203 (Fax)
STANFORD CANCER CENTER
875 Blake Wilbur Dr STE 2327B, Palo Alto 94304
(650) 736-1253 (Phone), (650) 724-5203 (Fax)
875 Blake Wilbur Dr STE 2324, Palo Alto 94304
(650) 498-6000 (Phone), (650) 724-5203 (Fax)
STANFORD CANCER CENTER
875 Blake Wilbur Dr STE 2327B, Palo Alto 94304
(650) 736-1253 (Phone), (650) 724-5203 (Fax)
Education:
Medical Schools
University of California At San Francisco
Graduated: 1998
University of California At San Francisco
Graduated: 1998
Humanized And Chimeric Monoclonal Antibodies To Cd47
US Patent:
2013014, Jun 6, 2013
Filed:
Nov 13, 2012
Appl. No.:
13/675274
Inventors:
The Board of Trustees of the Leland Stanford - Palo Alto CA, US
Irving L. Weissman - Stanford CA, US
Ravindra Majeti - Stanford CA, US
Irving L. Weissman - Stanford CA, US
Ravindra Majeti - Stanford CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C07K 16/28, G01N 33/68
US Classification:
4241331, 5303873, 536 2353, 4352542, 435328, 435 721
Abstract:
Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
Synergistic Anti-Cd47 Therapy For Hematologic Cancers
US Patent:
2012028, Nov 8, 2012
Filed:
Sep 15, 2010
Appl. No.:
13/394060
Inventors:
Irving L. Weissman - Stanford CA, US
Ravindra Majeti - Stanford CA, US
Arash Ash Alizadeh - San Mateo CA, US
Mark P. Chao - Mountain View CA, US
Ravindra Majeti - Stanford CA, US
Arash Ash Alizadeh - San Mateo CA, US
Mark P. Chao - Mountain View CA, US
International Classification:
A61K 39/395, A61K 51/10, C07K 16/30, A61P 35/00, A61P 35/02
US Classification:
424 149, 4241741, 5303873, 4241781
Abstract:
Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.
Methods For Manipulating Phagocytosis Mediated By Cd47
US Patent:
2009019, Jul 30, 2009
Filed:
Jan 15, 2009
Appl. No.:
12/321215
Inventors:
Catriona Helen M. Jamieson - La Jolla CA, US
Irving L. Weissman - Stanford CA, US
Siddhartha Jaiswal - San Francisco CA, US
Ravindra Majeti - Stanford CA, US
Irving L. Weissman - Stanford CA, US
Siddhartha Jaiswal - San Francisco CA, US
Ravindra Majeti - Stanford CA, US
International Classification:
A61K 39/395, C12N 5/08
US Classification:
4241361, 4241831, 435377
Abstract:
Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.
Methods Of Treating Acute Myeloid Leukemia By Blocking Cd47
US Patent:
2014006, Mar 6, 2014
Filed:
Jul 12, 2013
Appl. No.:
13/941276
Inventors:
Irving L. Weissman - Stanford CA, US
Ravindra Majeti - Stanford CA, US
Mark P. Chao - Mountain View CA, US
Ravindra Majeti - Stanford CA, US
Mark P. Chao - Mountain View CA, US
International Classification:
A61K 39/395
US Classification:
4241731
Abstract:
Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
Markers Of Acute Myeloid Leukemia Stem Cells
US Patent:
2011001, Jan 20, 2011
Filed:
Jul 14, 2010
Appl. No.:
12/836152
Inventors:
Ravindra Majeti - Stanford CA, US
Irving L. Weissman - Stanford CA, US
Irving L. Weissman - Stanford CA, US
International Classification:
C40B 30/04, C12Q 1/02, G01N 33/53, C12N 5/00, C12Q 1/68
US Classification:
506 9, 435 29, 435 71, 435375, 435 6
Abstract:
Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
Methods Of Treating Acute Myeloid Leukemia By Blocking Cd47
US Patent:
8562997, Oct 22, 2013
Filed:
Jul 15, 2010
Appl. No.:
12/837409
Inventors:
Siddhartha Jaiswal - San Francisco CA, US
Irving L. Weissman - Stanford CA, US
Ravindra Majeti - Stanford CA, US
Mark P. Chao - Mountain View CA, US
Irving L. Weissman - Stanford CA, US
Ravindra Majeti - Stanford CA, US
Mark P. Chao - Mountain View CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 39/395
US Classification:
4241731, 4241531, 4241561, 4241741
Abstract:
Methods are provided to manipulate phagocytosis of cancer cells, including e. g. leukemias, solid tumors including carcinomas, etc.